RT Journal Article
SR Electronic
T1 Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.27.23285092
DO 10.1101/2023.01.27.23285092
A1 Fadlyana, Eddy
A1 Dhamayanti, Meita
A1 Tarigan, Rodman
A1 Prodjosoewojo, Susantina
A1 Rahmadi, Andri Reza
A1 Sari, Rini Mulia
A1 Rusmil, Kusnandi
A1 Kartasasmita, Cissy B
YR 2023
UL http://medrxiv.org/content/early/2023/01/30/2023.01.27.23285092.abstract
AB Background One of the newest strategies developed by the Global Influenza Strategy has been to broaden the composition of the current influenza vaccine formulations from trivalent products to quadrivalent products. This study aimed to assess the immunogenicity and safety of Quadrivalent Influenza HA vaccine (QIV) compared with Trivalent Influenza HA vaccine (TIV) and to evaluate three consecutive batches of QIV equivalence in Indonesian children and adults.Methods and findings This was an open-labeled, bridging clinical study involving unprimed healthy children and adults aged 9–40 years. A total of 540 subjects were enrolled in this study and randomized into four arm groups. Each subject received one dose of TIV or QIV with three different batch codes. Serology tests were performed at baseline and 28 days after vaccination. Hemagglutination inhibition (HI) antibody titers were analyzed for Geometric Mean Titer (GMT), seroprotection, and seroconversion rates. Solicited, unsolicited, and serious adverse events were observed up to 28 days after vaccination. A total of 537 subjects completed the study per protocol and were analyzed for immunogenicity criteria. All randomized subjects were analyzed for safety criteria. The percentage of the subjects with anti-HI titer ≥1:40 28 days after QIV vaccination was 99.5% for A/H1N1; 99.5% for A/H3N2; 93.1% for B/Texas, and 99.0% for B/Phuket. The seroprotection, GMT, and seroconversion rates of QIV were not significantly different from those of TIV for the common vaccine strains (p > 0.01) and were significantly different from those of TIV for the added B/Phuket strains (p < 0.01). Most solicited injection-site and systemic reactions with either vaccine were mild to moderate and resolved within a few days.Conclusions QIV was immunogenic and well-tolerated and had immunogenicity and safety profiles compared with TIV for all common strains. The immunogenicity of the three batches of QIV was equivalent for the four strains.Clinical Trial registration NCT03336593Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: Novilia Sjafri Bachtiar and Rini Mulia Sari are employees of PT Bio Farma at the time of the conduct of this study and manuscript preparation.Clinical TrialNCT03336593Funding StatementYES - Funding for this trial was provided by PT Bio Farma Indonesia, no 04310/DIR/XI/2017, PO-00017403. PT Bio Farma Indonesia was involved in the study design, data collection, data analysis and preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Research Ethics Committee, Faculty of Medicine, Universitas PadjajaranI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript